Literature DB >> 10931803

PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans.

G Peri1, M Introna, D Corradi, G Iacuitti, S Signorini, F Avanzini, F Pizzetti, A P Maggioni, T Moccetti, M Metra, L D Cas, P Ghezzi, J D Sipe, G Re, G Olivetti, A Mantovani, R Latini.   

Abstract

BACKGROUND: Inflammation is an important component of ischemic heart disease. PTX3 is a long pentraxin whose expression is induced by cytokines in endothelial cells, mononuclear phagocytes, and myocardium. The possibility that PTX3 is altered in patients with acute myocardial infarction (AMI) has not yet been tested. METHODS AND
RESULTS: Blood samples were collected from 37 patients admitted to the coronary care unit (CCU) with symptoms of AMI. PTX3 plasma concentrations, as measured by ELISA, higher than the mean+2 SD of age-matched controls (2.01 ng/mL) were found in 27 patients within the first 24 hours of CCU admission. PTX3 peaked at 7.5 hours after CCU admission, and mean peak concentration was 6.94+/-11.26 ng/mL. Plasma concentrations of PTX3 returned to normal in all but 3 patients at hospital discharge and were unrelated to AMI site or extent, Killip class at entry, hours from symptom onset, and thrombolysis. C-reactive protein peaked in plasma at 24 hours after CCU admission, much later than PTX3 (P<0.001). Patients >64 years old and women had significantly higher PTX3 concentrations at 24 hours (P<0.05). PTX3 was detected by immunohistochemistry in normal but not in necrotic myocytes.
CONCLUSIONS: PTX3 is present in the intact myocardium, increases in the blood of patients with AMI, and disappears from damaged myocytes. We suggest that PTX3 is an early indicator of myocyte irreversible injury in ischemic cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10931803     DOI: 10.1161/01.cir.102.6.636

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  125 in total

1.  Effects of telmisartan on markers of ventricular remodeling in patients with acute myocardial infarction: comparison with enalapril.

Authors:  Takashi Yokota; Tomohiro Osanai; Kenji Hanada; Motoi Kushibiki; Naoki Abe; Koichi Oikawa; Hirofumi Tomita; Takumi Higuma; Jin Yokoyama; Hiroyuki Hanada; Ken Okumura
Journal:  Heart Vessels       Date:  2010-10-05       Impact factor: 2.037

2.  Risk factors for chronic kidney diseases may include periodontal diseases, as estimated by the correlations of plasma pentraxin-3 levels: a case-control study.

Authors:  A R Pradeep; Rahul Kathariya; P Arjun Raju; R Sushma Rani; Anuj Sharma; N M Raghavendra
Journal:  Int Urol Nephrol       Date:  2011-06-03       Impact factor: 2.370

3.  Aberrant methylation of the 3q25 tumor suppressor gene PTX3 in human esophageal squamous cell carcinoma.

Authors:  Jun-Xiong Wang; Yuan-Long He; Sheng-Tao Zhu; Shuo Yang; Shu-Tian Zhang
Journal:  World J Gastroenterol       Date:  2011-10-07       Impact factor: 5.742

4.  Differential associations of serum amyloid A and pentraxin-3 with allele-specific lipoprotein(a) levels in African Americans and Caucasians.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Zeynep Ozturk; Wei Zhang; Thomas A Pearson; Lars Berglund
Journal:  Transl Res       Date:  2011-02-05       Impact factor: 7.012

5.  Elevated plasma long pentraxin-3 levels and primary graft dysfunction after lung transplantation for idiopathic pulmonary fibrosis.

Authors:  J M Diamond; D J Lederer; S M Kawut; J Lee; V N Ahya; S Bellamy; S M Palmer; V N Lama; S Bhorade; M Crespo; E Demissie; J Sonett; K Wille; J Orens; P D Shah; A Weinacker; D Weill; B A Kohl; C C Deutschman; S Arcasoy; A S Shah; J A Belperio; D Wilkes; J M Reynolds; L B Ware; J D Christie
Journal:  Am J Transplant       Date:  2011-08-22       Impact factor: 8.086

6.  Relationship between plasma pentraxin 3 level and risk of chronic kidney disease in the Korean elderly: the Dong-gu study.

Authors:  Ran Lee; Min-Ho Shin; Hee-Nam Kim; Young-Hoon Lee; Seong-Woo Choi; Hye-Ran Ahn; Sun-Seog Kweon
Journal:  Int Urol Nephrol       Date:  2017-07-21       Impact factor: 2.370

7.  Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical atherosclerosis: evidence for association with atherogenic lipid profile.

Authors:  Michela Zanetti; Alessandra Bosutti; Clara Ferreira; Pierandrea Vinci; Gianni Biolo; Maurizio Fonda; Matteo Valente; Luigi Cattin; Gianfranco Guarnieri; Rocco Barazzoni
Journal:  Clin Exp Med       Date:  2009-02-24       Impact factor: 3.984

8.  Increased expression of long pentraxin PTX3 in inflammatory bowel diseases.

Authors:  Shingo Kato; Mitsuko Ochiai; Tomoya Sakurada; Shino Ohno; Kyoko Miyamoto; Mina Sagara; Masataka Ito; Kyoko Takeuchi; Junko Imaki; Kazuro Itoh; Koji Yakabi
Journal:  Dig Dis Sci       Date:  2007-11-08       Impact factor: 3.199

9.  Pentraxin 3 as a novel marker predicting congestive heart failure in subjects with acute coronary syndrome.

Authors:  Dong-Hyeon Lee; Hui-Kyung Jeon; Ji-Han You; Mi-Yeon Park; Seung-Jae Lee; Sung-Sik Kim; Byung-Joo Shim; Yun-Seok Choi; Woo-Seung Shin; Jong-Min Lee; Chul-Soo Park; Ho-Joong Youn; Wook-Sung Chung; Jae-Hyung Kim
Journal:  Korean Circ J       Date:  2010-08-31       Impact factor: 3.243

10.  Plasma Pentraxin3 is a novel marker for nonalcoholic steatohepatitis (NASH).

Authors:  Masato Yoneda; Takashi Uchiyama; Shingo Kato; Hiroki Endo; Koji Fujita; Kyoko Yoneda; Hironori Mawatari; Hiroshi Iida; Hirokazu Takahashi; Hiroyuki Kirikoshi; Masahiko Inamori; Yuichi Nozaki; Noritoshi Kobayashi; Kensuke Kubota; Satoru Saito; Shiro Maeyama; Mina Sagara; Hiroyuki Aburatani; Tatsuhiko Kodama; Atsushi Nakajima
Journal:  BMC Gastroenterol       Date:  2008-11-14       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.